In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain

  • E. Ríos Dueñas
  • I. Rodríguez-Avial
  • J. J. Picazo
Article

Abstract

The in vitro activity of ceftobiprole was compared with that of seven antimicrobial agents against invasive Streptococcus pneumoniae isolated from adult patients (>15 years old). Characterization of erythromycin-resistant strains and serotype distribution of all pneumococci were also evaluated. Seventy invasive S. pneumoniae strains were isolated from December 2007 to January 2009. Serotyping was carried out by Quellung reaction. Antibiotic susceptibility was tested by broth microdilution (CLSI guidelines). The comparator agents were penicillin, cefotaxime, erythromycin, clindamycin, telithromycin, tetracycline and moxifloxacin. Phenotypic characterization of macrolide resistance was performed by the double disk method. Macrolide resistance genes [erm(B) and mef(A/E)] and the promoter of erm(B) were detected by PCR. Twenty-five different serotypes were detected of which 87% were non-PCV7 types. The percentages of resistance to erythromycin, clindamycin and tetracycline were 20%, 8.6% and 16%, respectively. A penicillin MIC ≥0.12 mg/L was observed in 14 of the 70 invasive pneumococci strains. The cefotaxime and ceftobiprole MIC50/MIC90 of these 14 strains were 1/4 and 0.03/1 mg/L, respectively. Ceftobiprole showed higher in vitro activity than penicillin and cefotaxime with all isolates being inhibited by ≤1 mg/L. Its high in vitro activity should make ceftobiprole a very promising drug for the treatment of pneumococcal infections.

References

  1. 1.
    Ardanuy C, Tubau F, Pallares R, Calatayud L, Dominguez Maria A, Rolo D, Grau I, Martin R, Liñares J (2009) Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997–2007. Clin Microbiol Infect 48(1):57–64Google Scholar
  2. 2.
    Fenoll A, Granizo JJ, Aguilar L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G, Casal J, Tarrago D (2009) Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47(4):1012–1020PubMedCrossRefGoogle Scholar
  3. 3.
    Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG, for the Active Bacterial Core Surveillance T (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294(16):2043–2051PubMedCrossRefGoogle Scholar
  4. 4.
    Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia Juan J, Pallares R (2008) Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46(2):174–182PubMedCrossRefGoogle Scholar
  5. 5.
    Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, the Active Bacterial Core Surveillance of the Emerging Infections Program N (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348(18):1737–1746PubMedCrossRefGoogle Scholar
  6. 6.
    Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo F, Hernandez-Sampelayo T, Otheo E, Balboa F, Rios E, Mendez C (2011) Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 18(1):89–94PubMedCrossRefGoogle Scholar
  7. 7.
    Dagan R (2009) Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 15:16–20PubMedCrossRefGoogle Scholar
  8. 8.
    Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance of the Emerging Infections Program N (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354(14):1455–1463PubMedCrossRefGoogle Scholar
  9. 9.
    Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MGP, Then RL (2001) In vitro and In vivo properties of Ro 63–9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococci. Antimicrob Agents Chemother 45(3):825–836PubMedCrossRefGoogle Scholar
  10. 10.
    Kosowska K, Hoellman DB, Lin G, Clark C, Credito K, McGhee P, Dewasse B, Bozdogan B, Shapiro S, Appelbaum PC (2005) Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 49(5):1932–1942PubMedCrossRefGoogle Scholar
  11. 11.
    Davies TA, Shang W, Bush K (2006) Activities of ceftobiprole and other {beta}-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother 50(7):2530–2532PubMedCrossRefGoogle Scholar
  12. 12.
    Deshpande LM, Jones RN (2003) Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 9(11):1120–1124PubMedCrossRefGoogle Scholar
  13. 13.
    Clinical Laboratory Standards Institute C (2008) Performance standards for antimicrobial susceptibility testing; 18th informational supplement M100-S18. Wayne, PA, USAGoogle Scholar
  14. 14.
    Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L (1996) Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 40(11):2562–2566PubMedGoogle Scholar
  15. 15.
    Rosato A, Vicarini H, Leclercq R (1999) Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J Antimicrob Chemother 43(4):559–562PubMedCrossRefGoogle Scholar
  16. 16.
    Daly MM, Doktor S, Flamm R, Shortridge D (2004) Characterization and Prevalence of mefA, mefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates. J Antimicrob Chemother 42:3570–3574Google Scholar
  17. 17.
    Hicks LA, Harrison LH, Flannery B, Hadler J, Schaffner W, Craig A, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley M, Whitney C (2007) Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 196(9):1346–1354PubMedCrossRefGoogle Scholar
  18. 18.
    Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, P-Y EG (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 28:731–738PubMedCrossRefGoogle Scholar
  19. 19.
    Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Linares J (2009) Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother 64:507–510PubMedCrossRefGoogle Scholar
  20. 20.
    Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison L, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B (2008) Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197(7):1016–1027PubMedCrossRefGoogle Scholar
  21. 21.
    Calatayud L, Ardanuy C, Tubau F, Rolo D, Grau I, Pallares R, Martin R, Linares J (2010) Serotype and genotype replacement among macrolide-resistant invasive pneumococci in adults: mechanisms of resistance and association with different transposons. J Clin Microbiol 48(4):1310–1316PubMedCrossRefGoogle Scholar
  22. 22.
    Song J-H (2008) What's new on the antimicrobial horizon? Int J Antimicrob Agents 32(Suppl 4):S207–S213PubMedCrossRefGoogle Scholar
  23. 23.
    Pillar CM, Aranza MK, Shah D, Sahm DF (2008) In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J Antimicrob Chemother 61(3):595–602PubMedCrossRefGoogle Scholar
  24. 24.
    Betriu C, Culebras E, Gómez M, López-Fabal F, Rodríguez-Avial I, Picazo JJ (2010) Comparative in vitro activity of ceftobiprole against Gram-positive cocci. Int J Antimicrob Agents 36(2):111–113PubMedCrossRefGoogle Scholar
  25. 25.
    Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ (2002) In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 50(6):915–932PubMedCrossRefGoogle Scholar
  26. 26.
    Barbour A, Schmidt S, Rand KH, Derendorf H (2009) Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 34(1):1–7PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • E. Ríos Dueñas
    • 1
  • I. Rodríguez-Avial
    • 1
  • J. J. Picazo
    • 1
  1. 1.Servicio de Microbiología, Hospital Clínico San CarlosMadridSpain

Personalised recommendations